Articles tagged with: SEA-BCMA

Press Releases»

[ by | Nov 14, 2018 8:00 am | Comments Off ]
  • SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma
  • Adds to Seattle Genetics’ Robust Clinical-Stage Development Pipeline across Multiple Hematologic and Solid Tumors

Bothell, WA (Press Release) – Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clin­i­cal trial eval­u­ating the safety and tolerability of SEA-BCMA for patients with re­lapsed or refractory multiple myeloma (MM). SEA-BCMA is an inves­ti­ga­tional anti­body empowered using Seattle Genetics’ pro­pri­e­tary Sugar Engineered Antibody (SEA) tech­nology designed to en­hance anti­body dependent cellular cyto­tox­icity. …

Read the full story »